Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 VMX-C001 versus usual pharmacological care for urgent high-bleeding-risk surgery in patients taking factor Xa direct oral anticoagulants
NL-OMON61158Phase 3Not yet recruiting
- Sponsor
- VarmX
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of VMX-C001, sponsored by VarmX. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
VMX-C001
Beyond the preview
Go deeper on NL-OMON61158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61158.